Hartman Mark L, Weltman Arthur, Zagar Anthony, Qualy Rebecca L, Hoffman Andrew R, Merriam George R
Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285, USA.
J Clin Endocrinol Metab. 2008 Jan;93(1):125-30. doi: 10.1210/jc.2007-1430. Epub 2007 Oct 23.
Several studies have demonstrated an improvement in aerobic exercise capacity with 6 months of GH replacement in adults with GH deficiency (GHD).
The objective of the study was to determine whether improvements in aerobic exercise capacity with GH treatment in adults with GHD are related to changes in physical activity or affected by the GH dosing regimen.
This was a randomized, two-arm, parallel, open-label study.
The study was conducted at five academic medical centers with exercise physiology laboratories.
Study subjects were adults (n = 29) with GHD due to hypothalamic-pituitary disease.
The intervention was GH replacement therapy, administered either as a fixed body weight-based dosing regimen as an individualized dose titration regimen for 32 wk.
Maximal oxygen consumption (VO2 max) and oxygen consumption (VO2) at the lactate threshold, ventilatory threshold using a cycle ergometry protocol, and weekly energy expenditure (physical activity questionnaire), assessed at baseline and end point, were measured.
In the group as a whole, VO2 max increased significantly (by 9%) from baseline (19.1+/- 0.89 ml/kg.min) to end point (21.6 +/- 1.23 ml/kg.min, P = 0.010). Compared with baseline, VO2 max also changed significantly within the individualized dose titration regimen group (+2.5 +/- 0.98 ml/kg.min, P =0.034) but not within the fixed body weight-based dosing regimen group (+1.2 +/- 0.78 ml/kg.min, P = 0.15), although these changes from baseline were not significantly different between the two groups. VO2 at lactate threshold, VO2 at ventilatory threshold, and weekly energy expenditure also did not change.
GH replacement therapy in GH-deficient adults improved VO2 max similarly with both dosing regimens, without any influence of physical activity. There was no effect on submaximal exercise performance.
多项研究表明,生长激素缺乏症(GHD)成人接受6个月的生长激素替代治疗后,有氧运动能力有所改善。
本研究的目的是确定GHD成人接受生长激素治疗后有氧运动能力的改善是否与体力活动的变化有关,或受生长激素给药方案的影响。
这是一项随机、双臂、平行、开放标签研究。
该研究在五个设有运动生理学实验室的学术医疗中心进行。
研究对象为因下丘脑-垂体疾病导致GHD的成人(n = 29)。
干预措施为生长激素替代疗法,以基于固定体重的给药方案或个体化剂量滴定方案给药32周。
使用自行车测力计方案,在基线和终点评估最大耗氧量(VO2 max)、乳酸阈值时的耗氧量(VO2)、通气阈值,并测量每周能量消耗(体力活动问卷)。
总体而言,VO2 max从基线时的(19.1±0.89毫升/千克·分钟)显著增加(9%)至终点时的(21.6±1.23毫升/千克·分钟,P = 0.010)。与基线相比,个体化剂量滴定方案组的VO2 max也有显著变化(增加2.5±0.98毫升/千克·分钟,P = 0.034),但基于固定体重的给药方案组没有变化(增加1.2±0.78毫升/千克·分钟,P = 0.15),尽管两组从基线开始的这些变化没有显著差异。乳酸阈值时的VO2、通气阈值时的VO2和每周能量消耗也没有变化。
两种给药方案对GHD成人进行生长激素替代治疗时,VO2 max的改善相似,且不受体力活动的影响。对次最大运动表现没有影响。